Brand name : Pomalong
Active ingredient : Pomalidomide
Manufactured : Cipla Ltd
Strength : 1mg
Pack : 21 capsules in a container
Category : Anti-neoplastic drug
Pomalong 1mg is a Sun Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide.
Pomalong 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;
Pomalong 1mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment.
This may lead to severe liver injury.
Pomalong 1mg is involved in the treatment for regression & unmanageable multiple myeloma.
Pomalong 1mg is used in the patients who are failing to response for Lenalidomide treatment.
Pomalong 1mg is used in combination with dexamethasone.
The major therapeutic indication of Pomalong 1mg is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalong 1mgomide.
Pomalong 1mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
DOSAGE & ADMINISTRATION
The prescribed dose of Pomalong in multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.
Pomalong 1mg should be concomitant with dexamethasone.
Pomalong 1mg Capsules should be taken with or without food.
During hematological toxicities:
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalong therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomalong 3mg daily.
Platelets count <25,000/mcL: postpone the Pomalong treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomalong
Pomalong 1mg with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomalong by 50%
In renal impairment:
Initial dose of Pomalong is 3mg
In hepatic impairment:
Mild to moderate condition, an initial dose of Pomalong is 3mg; in severe condition, the initial dose of Pomalong is 2mg.
Pomalong 1mg exhibits various activities like;
Promote apoptosis of hematopoietic cancer cells
Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Boosted the T-cells & natural killer cell mediate immunity.
The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Interfere with formation of new vessels and leads to inhibit the cell division.
There are two major worsening condition may occur during the treatment using with Pomalong 1mg.
Embryo fetal damage :
Pomalong 1mg Capsules are contraindicated to pregnancy period.
During the treatment, patients avoid to becoming pregnant.
Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism :
Patient who are receiving Pomalong 1mg Capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke.
This type of condition should be treated by initiating prophylactic anti-thrombotic drugs.
The patients who are acquiring this condition then thromboprophylaxis should be provided
Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4.
The concomitant use of Pomalong 1mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomalong leads to higher extent of adverse effects associated with Pomalid
In this condition, reduce the dose of Pomalong 1mg and recommended.
Pomalong 1mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomalong 1mg is X.
More common effects :
If taken during pregnancy, Severe life-threatening human birth defects
Fatigue, Weakness, Low white blood cell count, Anemia, Constipation, Nausea, Diarrhea, Shortness of breath, Upper respiratory infections, Back pain, Fever.
Less common effects :
Neuropathy , Dizziness, Confusion.